Dendritic Cells Immunobiology and Cancer Immunotherapy by Ardavı́n, Carlos et al.
Immunity, Vol. 20, 17–23, January, 2004, Copyright 2004 by Cell Press
Meeting ReportDendritic Cells: Immunobiology
and Cancer Immunotherapy
vaccination and cancer immunotherapy protocols, and
other in vivo approaches.
Conscious of the importance of DCs in the control of
Carlos Ardavı´n,1,* Sebastia´n Amigorena,2
and Caetano Reis e Sousa3
1Department of Cell Biology
Faculty of Biology immunity and of the therapeutic potential of DC vaccina-
tion, the Juan March Foundation sponsored a workshopComplutense University
28040 Madrid on “Dendritic Cells: Biology and Therapeutic Applica-
tions,” which was organized by Ralph Steinman (Rocke-Spain
2 U365 Institut National de la Sante´ feller University, New York, USA), Ignacio Melero (Uni-
versidad de Navarra, Pamplona, Spain), and Angel Corbı´et de la Recherche Me´dicale
Institut Curie (Centro de Investigaciones Biolo´gicas, Madrid, Spain)
and took place in Madrid, October 6–8, 2003.Section Recherche
26 rue d’Ulm
75005 Paris DC Immunobiology
France DCs are generated from either myeloid or lymphoid bone
3 Cancer Research UK marrow progenitors through intermediate DC precur-
London Research Institute sors that home to sites of potential antigen entry, where
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London WC2A 3PX gen capture in the presence of maturation signals asso-
United Kingdom ciated with inflammation or infection, immature DCs are
activated by TLRs, interferons (IFNs), or members of
TNF-R family and undergo a complex maturation pro-
A recent workshop on “Dendritic Cells: Biology and cess. In vivo this process is paralleled by migration of
Therapeutic Applications,” sponsored by the Juan DCs to T cell-rich areas of lymphoid organs, where they
March Foundation, brought together basic and clinical present antigen-derived peptides to antigen-specific
research scientists to discuss the mechanisms under- T cells and direct their differentiation into T effector or
lying the control of immune responses and tolerance memory cells. In addition, mature DCs can induce NK
by dendritic cells (DCs), as well as recent research cell activation and B cell differentiation into antibody-
in cancer immunotherapy based on DC vaccination. forming cells. In contrast, antigen capture in the absence
Particular emphasis was placed on antigen processing of activation stimuli may lead to the induction of T cell
and presentation by DCs, C-type lectin antigen recep- tolerance, as a result of antigen presentation by imma-
tors, DC maturation and polarization of T cell responses, ture DCs in the absence of costimulation. An integrated
the control of immunity versus tolerance by DCs, the view of DC immunobiology is shown in Figure 2.
developmental origin of DCs, and the use of DCs in
cancer immunotherapy. Mechanisms of Antigen Processing and Presentation
by DCs
The past decade has been marked by spectacular prog- Rolf Zinkernagel (Zurich, Switzerland) gave the opening
ress toward understanding how dendritic cells (DCs) presentation in this meeting. He presented experiments
control the immune system, arising from intensive work examining crosspresentation and crosspriming by tu-
dealing with a large diversity of DC research fields, as mor cells expressing various viral antigens. No cross-
summarized in Figure 1. These include the description priming was detectable in vivo, nor was protection via
of the mechanisms underlying the processing and pre- such a mechanism demonstrable. Recent experiments
sentation of antigens derived from pathogens, apoptotic revealed that poliovirus prime CTLs in normal C57B/6
and tumor cells, the organization of the DC-T cell im- mice and that polioviral antigens are translated in recep-
mune synapse, the discovery of C-type lectin receptors tor-negative mice. Therefore, the original assumption of
for antigen capture, the control of DC activation by Toll- a need for crosspriming in immune responses against
like receptors (TLRs), the relevance of plasmacytoid DCs poliovirus in mice was questioned (Freigang et al., 2003).
(pDCs) in antiviral responses, the role of DCs in polariz- Zinkernagel concluded that while crosspriming cannot
ing T helper cell responses, the regulation of natural killer be absolutely excluded, its efficiency is at least a 1000
(NK) and B cell responses, the in vivo analysis of DC to 10,000 times less than direct presentation on MHC
traffic and immune interactions, the control of immunity class I.
versus tolerance by DCs, the role of DCs in microbial However, crosspresentation may be much more effi-
infections, autoimmune disorders, allergic reactions, cient for certain particulates. Sebastian Amigorena
graft rejection, and antitumor immune responses, and (Paris, France) presented a recent study of the pathways
the differentiation pathways of DCs. These advances in involved in DC crosspresentation of such antigens. He
DC immunobiology, together with the improvement of showed that newly formed phagosomes in DCs rapidly
DC transfection and in vitro differentiation techniques, fuse with elements of the endoplasmic reticulum, thereby
have allowed the development of promising DC-based bringing the MHC class I loading machinery into the
endocytic compartment. These phagosomes can then
function as self-contained MHC class I loading compart-*Correspondence: ardavin@bio.ucm.es
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Figure 1. Diagram Summarizing the Main Current Research Topics Related to DCs
ments, allowing any phagosomal antigens escaping to Maria Mittelbrunn (Madrid, Spain) showed that in the
presence of antigen, the 1 integrin VLA-4 is recruitedthe cytosol to be rapidly processed by proteasomes and
reimported via TAP (Guermonprez et al., 2003). Thus, to the periphery of the immune synapse, colocalizing
with LFA-1. She further addressed the role of VLA-4 inphagosomal loading favors crosspresentation by dimin-
ishing competition between exogenous antigens and T cell activation by showing that VLA-4 engagement
regulates Th1 responses both in vitro and in vivo. Finally,endogenous antigens, which are loaded in the endoplas-
mic reticulum. she reported a protective effect of treatment with anti-
VLA-4 antibodies in a model of autoimmune nephritisEvelina Gatti (Marseille, France) presented a recent
study about the regulation of the degradation of defec- by balancing Th responses.
tive ribosomal products (DRiPs) in DCs. DRiPs, which
account for almost 30% of newly synthesized proteins, C-Type Lectin Antigen Receptors
C-type lectins expressed on immature DCs represent anrepresent the main source of MHC class I-restricted
peptides. At the onset of maturation DCs specifically important class of antigen receptors, which recognize
glycosylated structures (reviewed in Figdor et al., 2002).aggregate ubiquitinated DRiPs and form dendritic cell
aggresome-like inducible structures (DALIS) (Lelouard C-type lectins may not only function as receptors medi-
ating the internalization and processing of pathogenset al., 2002). These structures accumulate transiently in
the cell and delay the degradation of DRiPS, although to enhance antigen presentation by DCs, but could also
mediate cell adhesion and signaling.proteasome function itself is not affected. Accumulation
of DRiPs is likely to influence MHC class I presentation. The latter was highlighted by Yvette van Kooyk (Am-
sterdam, The Netherlands) who discussed a novel high-In agreement with this hypothesis, she showed that at
the onset of maturation MHC class I-peptide complexes affinity cellular interaction between granulocytes and
DCs. This involves the recognition of nonsialylated Lewisxare rapidly and transiently downregulated and that the
kinetics of this downregulation correlates with the for- expressed by the neutrophil receptors CD11b and
CD66a by the C-type lectin DC-SIGN expressed on DCs.mation of DALIS.
Francisco Sa´nchez Madrid (Madrid, Spain) discussed She further reminded us that DC-SIGN seems to be
targeted by many different pathogens (viruses, bacteria,recent findings on the dynamics of initial exploratory
interactions between T lymphocytes and DCs (Mittel- yeast, and parasites) to escape immunity by subverting
intracellular trafficking or interfering with DC activationbrunn et al., 2002; Montoya et al., 2002). Live time-lapse
confocal microscopy analyses of GFP adhesion mole- (van Kooyk and Geijtenbeek, 2003). For example, DC-
SIGN mediates HIV internalization, but viral particlescules transfected in T cells and DCs revealed that
ICAM-1, ICAM-3, and LFA-1 are involved in the early stay in early endosomes and are transported again to
the cell surface, allowing HIV to mediate T cell infectionadhesive T-DC contacts at both T and DC sides.
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Figure 2. Integrated View of DC Immunobiology
in trans. Similarly, ManLAM from Mycobacterium tuber- application of this technology to a recombinant soluble
form of murine SIGN-R1, which, in conjunction with bind-culosis binds to DC-SIGN and alters DC maturation by
interfering with TLR signaling (Geijtenbeek et al., 2003). ing experiments with SIGN-R1-transfected cells, has re-
vealed that high-affinity ligands for this receptor areThis suggests that DC-SIGN could have a primary func-
tion in recognizing self-antigen and maintaining self- mannosyl-fucosyl glycans, whereas dextran is a low-
affinity ligand.tolerance, which is exploited by pathogens to suppress
immune activation. Eirikur Saeland (Amsterdam, The Netherlands) ex-
panded the topic of DC-expressed C-type lectins to aThe involvement of DC-SIGN in pathogen recognition
was further highlighted by Angel Corbı´ (Madrid, Spain) discussion of their possible function in recognition of
tumor antigens, some of which, such as MUC1, can bewho addressed how DC-SIGN mediates the interaction
of DCs with clinically relevant parasite and fungal patho- aberrantly glycosylated. By studying the interaction of
recombinant MUC1 with human DCs, he identified MGLgens, and how the level of expression of DC-SIGN differ-
entially affects its adhesion and pathogen recognition (macrophage Gal/GalNAc specific C-type lectin) as a
receptor for tumor-associated MUC1 and showed thatabilities. He further showed that DC-SIGN engagement
on the cell surface triggers intracellular signals, which binding was dependent on the particular glycoform in
question. Further elucidation of MGL recognition couldcould potentially affect the DC maturation process.
However, it remains unclear whether this signaling signi- extend the potential of MUC1 as a target for immuno-
therapy.fied that DC-SIGN functions as an actual pattern-recog-
nition receptor, leading to DC activation, or modulates
TLR-initiated signals. Other C-type lectins are likely to
also bind pathogens, but pinpointing their carbohydrate DC Activation and Polarization of T Cell Responses
TLRs function as sensors of microbial infection and playligands remains a challenging area of cell biology, as
oligosaccharides cannot be readily cloned, each being a critical role in the induction of innate and adaptive
immune responses (reviewed in Kopp and Medzhitov,the product of multiple glycosyltransferases.
Ten Feizi (London, UK) discussed a carbohydrate mi- 2003). TLR-mediated DC activation and maturation,
which are dependent on NF-B and MAP kinase signal-croarray system for generating large repertoires of im-
mobilized oligosaccharide probes, which is proving to ing pathways, lead to upregulation of MHC and costimu-
latory molecules, as well as production of cytokines andbe a powerful means both of detecting protein-carbohy-
drate interactions and assigning the sequences recog- other soluble factors. Together, these act to sustain the
clonal expansion of newly activated T cells and theirnized (reviewed in Feizi et al., 2003). She described the
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differentiation into effectors to determine the polariza- expansion was induced (Fujii et al., 2003). Anti-DEC-OVA
conjugates stayed for long periods after injection in thetion of T helper cell responses.
lymph nodes, inducing a prolonged and systemic anti-Caetano Reis e Sousa (London, UK) showed that DC
gen presentation to OVA-specific T cells. Antigen tar-maturation can be induced by TLR ligands but that it can
geting via DEC-205 resulted in stronger effector T cellalso occur in response to signals from newly activated
responses than those obtained with antigen-pulsed exCD4 T cells independently of innate priming. T cell-
vivo-derived DCs or antigen in complete Freund’s adju-driven DC maturation takes place both in cis and in
vant. Finally, Steinman underscored the importance oftrans, affecting all DCs in the microenvironment, includ-
DC maturation for the induction of effective T cell re-ing ones that do not bear specific antigen. In contrast,
sponses by showing that OVA-specific effector T cellIL-12 production by DCs shows an absolute requirement
development was significantly enhanced when antigenfor TLR signals and can only be amplified, but not initi-
presentation was concurrent with influenza infection.ated, by signals from newly activated CD4 T cells deliv-
Michel Nussenweig (New York, USA) discussed recentered in cis (Spo¨rri and Reis e Sousa, 2003).
data on the mechanisms controlling the induction ofThe role of TLR-mediated induction of costimulation
T cell tolerance by DCs using a model of experimentaland cytokines in DCs was further discussed by Ruslan
allergic encephalomyelitis (EAE), induced by treatmentMedzhitov (New Haven, USA) who showed that in addi-
with the MOG peptide, derived from the myelin oligoden-tion to the upregulation of costimulation by DCs, TLRs
drocyte protein, in complete Freund’s adjuvant. He re-induce a cytokine-dependent blockade of T regulatory
ported that treatment with conjugates of anti-DEC-205(Treg) cell suppression, mediated by IL-6 (Pasare and
with the MOG peptide (DEC-MOG) prevented the devel-Medzhitov, 2003). On the basis of the analysis of MyD88-
opment of EAE. Injection of anti-DEC-MOG determineddeficient mice, he concluded that TLR-induced cytokine
the differentiation of nonanergic, unresponsive MOG-production and block of Treg cells was MyD88 depen-
specific T cells, without Treg cell function.dent both in vitro and in vivo. He finally emphasized the
Antonio Lanzavecchia (Bellinzona, Switzerland) em-importance of TLRs in T cell activation by showing that
phasized the importance of “tissue conditioning” for DCno DC-induced T cell activation occurs in the absence
migration by showing that CCR7-dependent DC migra-of TLR ligands in response to “pure antigens,” i.e., not
tion to the lymph nodes was increased after a first injec-containing TLR ligands. Thus, innate signals promote
tion of DCs or after treatment of the injection area withimmunity by controlling multiple parameters of T cell
TNF- or IL-1, which correlated with the upregulationpriming by DCs.
of the CCR7 ligand SLC by the lymphatic endotheliumThe concept that polarization of T helper responses
(MartIn-Fontecha et al., 2003). In the second part of hisrelies on specialized DC subsets was challenged by
talk, he showed data supporting a model of progressiveAnne O’Garra (London, UK). She reported that different
T cell differentiation, proposing that the signal strengthDC subpopulations either differentiated in vitro or iso-
resulting from the DC-T cell interaction determines thelated from the spleen can induce Th1 or Th2 effector
fate of the responding T cells (Gett et al., 2003). Lowcells in vitro depending on the antigen dose and the
signal strength induced the proliferation of naive T cellsactivation stimulus. High antigen doses induced a Th1
but not the acquisition of effector function. At higherresponse, while low doses induced a Th2 cytokine pro-
signal strength T cells acquire effector function and thefile (Boonstra et al., 2003). On the other hand, the capac-
capacity to migrate to inflamed tissues, while evenity of myeloid DCs versus pDCs to induce Th1 responses
higher signal strength induced T cell death. Finally, Lan-was shown to be dependent on activation with LPS and
zavecchia presented exciting data showing that activa-CpG, respectively, correlating with the high expression
tion of pDCs induced the upregulation of CXCR5 andof TLR4 and TLR9 by myeloid DCs and pDCs.
the production of its ligand BCA1/CXCL13, suggesting
a role for pDCs in mediating the formation of T cell-B
Control of Immunity and Tolerance by DCs cell interactions within B cell follicles.
Recent data have evidenced that, in addition to their The pivotal role of type I (, ) and type II () IFNs
role in the induction of effector T cell responses, DCs in the reciprocal activation of NK cells and DCs was
have an important role in peripheral tolerance. Induction addressed by Giorgio Trinchieri (Dardilly, France). He
of tolerance by DCs occurs in the steady state as a reported that IL-2-activated NK cells induced the matu-
consequence of antigen presentation in the absence of ration of monocyte-derived DCs by a mechanism requir-
inflammation or infection, and can be ascribed in differ- ing IFN- production by NK cells, as well as cell contact
ent settings to T cell deletion, T cell anergy, or the induc- (Gerosa et al., 2002). IL-2-activated NK cells can also
tion of Treg cells (reviewed in Steinman et al., 2003). induce pDC maturation and production of IFN-, which
Ralph Steinman (New York, USA) emphasized the po- can be further increased in the presence of CpG. Con-
tential of antigen targeting to DCs via antigen receptors versely, when activated by virus, CpG or CD40L, pDCs
for DC-mediated vaccination. By using an experimental acquire the capacity to activate resting NK cells by a
system based on the injection of conjugates of oval- cell contact-independent mechanism that can be blocked
bumin (OVA) linked to antibodies against the C-type with anti-IFN- antibodies. These data support a se-
lectin DEC-205 (anti-DEC-OVA), he showed that in the quential model of NK-DC activation that proposes that
steady state, OVA-loaded DCs via anti-DEC-OVA effi- activated pDCs secreting type I IFNs induce NK cell
ciently presented OVA to both MHC I- or MHC II-restricted activation; activated NK cells then produce IFN- which
T cells to induce peripheral tolerance (Bonifaz et al., 2002). induces the maturation of myeloid DCs and pDCs. Fi-
In contrast, when anti-DEC-OVA was injected together nally, Trinchieri underscored the role of NK cells in IFN-
production after TLR8 engagement by the antiviral com-with anti-CD40 or -galactosylceramide, strong T cell
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pound R-848 (imidazoquinoline resiquimod), in a pro- showed that CD11c DCs resident in vivo in the human
postnatal thymus are truly myeloid DCs, as they developcess requiring the participation of myeloid CD11c DCs.
Lieping Chen (Rochester, USA) presented data on a from CD34 early thymic progenitors through CD34lo
intermediates with upregulated GM-CSF receptor ex-new costimulatory pathway including B7-H1, B7-DC, PD-1,
and possibly another costimulatory receptor (Wang et pression, which branch off the main intrathymic devel-
opmental pathway and lose the capacity to generateal., 2003). B7-H1 is a costimulatory molecule belonging
to the category of dual function costimulators, which can T cells, but display myelomonocytic potential (de Ye-
benes et al., 2002). She also showed that this decisiondisplay either stimulatory or inhibitory function. Several
published studies analyzing mice deficient for PD-1 (pro- point is influenced by Notch1, since overexpression of
an activated form of this receptor, shown to affect intra-grammed death-1), a ligand for both B7-H1 and B7-DC,
support its inhibitory role since PD-1/ mice develop thymic differentiation of human T cells (Garcia-Peydro
et al., 2003), prevents early thymic progenitors fromautoimmune diseases. Expression of B7-H1 by tumor
cells induces deletion of activated T cells, again support- adopting a myeloid cell fate and simultaneously blocks
development of DCs. These data challenge the currenting the inhibitory function of the B7-H1/PD-1 interaction.
In contrast, treatment with blocking anti-B7-H1 mono- view that the thymus is colonized by a lymphoid-restricted
progenitor and provide evidence that a more immatureclonal antibodies suppressed the development of chronic
intestinal inflammation and reduced the production of lymphomyeloid precursor population is actually seeding
the human postnatal thymus.IFN-, IL-2, and TNF- by intestinal CD4 T cells (Kanai
et al., 2003). Comparative molecular modeling followed Gwendalyn Randolph (New York, USA) underlined the
differential migration properties of human monocyte sub-by site-directed mutagenesis revealed B7-H1 mutants
that do not bind PD-1 induce proliferation and IFN- sets, defined on the basis of the expression of CD16
(FcRIII). Using an in vitro system, she showed thatproduction by T cells. These data suggest that B7-H1-
mediated T cell activation involves the interaction of B7- CD16 were more effective than CD16 monocytes in
reverse transmigration and differentiation into DCsH1 with an as yet unidentified costimulatory ligand for
B7-H1. (Randolph et al., 2002). Others have reported that CD16
and CD16 subsets share patterns of chemokine recep-The role of costimulatory signaling in DC-mediated
T cell stimulation was further underlined by Tahiro Shin tor expression with mouse Gr-1 and Gr-1 monocytes,
respectively, which have been shown to display distinct(Baltimore, USA) who addressed the function of a novel
costimulatory molecule B7-DC, whose expression is re- trafficking and differentiation behavior. She showed that
further similarities between CD16 human monocytesstricted to DCs. B7-DC appears to synergize with B7-1
and B7-2 in the induction of CD4 T cell proliferation and F4/80 CD115 Gr-1 mouse monocytes included
higher expression of costimulatory molecules than other(Shin et al., 2003). Analysis of B7-DC-deficient mice
highlighted the role of this molecule in the initiation of monocytes. The Gr-1 subset of monocytes was found
to be nearly absent in CCR8-deficient mouse blood, andCD4 T cell responses, since proliferation of naive, but
not activated, CD4T cells was disminished in B7-DC/ CCR8/ had defects in the differentiation of monocytes
into DCs. Anti-CCR8 antibodies blocked human mono-mice. Experiments performed with B7-DC/ mice or
involving a treatment with anti-B7-DC-blocking antibod- cyte reverse transmigration in vitro. In conclusion, she
suggested that both CD115 Gr-1 mouse monocytesies suggest a role for this molecule in the induction of
Th1 responses. and CD16 human monocytes readily develop into DCs
via CCR8-mediated signals.
Origin and Precursors of DCs
Carlos Ardavı´n (Madrid, Spain) discussed recent data DC-Based Cancer Immunotherapy
In the last session of this meeting, several recent ap-derived mostly from in vivo DC reconstitution assays in
the mouse showing that the same DC subpopulations, proaches aimed at optimizing the use of DCs in immuno-
therapy were reported. Attempts to induce effective im-including conventional DCs and pDCs, can be generated
from either myeloid or lymphoid progenitors (reviewed mune responses were based on the use of DCs or tumor
cells as vectors, in association with either the expressionin Ardavı´n, 2003). These experiments do not support
the existence of independent myeloid and lymphoid DC of recombinant cytokines or T cell costimulation mole-
cules, or with monoclonal antibodies that boost immu-subpopulations as previously proposed but instead
point to a DC differentiation model relying on a dual nity, either by stimulating DCs or T cells, or by blocking
Treg cells (reviewed in Schuler et al., 2003).contribution of myeloid and lymphoid differentiation
pathways. However, different experimental approaches Ralph Steinman presented results from a phase I clini-
cal trial performed by the research group of Jacquessuggest that in vivo pDCs derive from the lymphoid
lineage. Carlos Ardavı´n also presented data suggesting Banchereau (Dallas, USA), in which CD34 precursors
were differentiated into mature DCs, loaded with tumorthat, during microbial infections, blood-borne DC pre-
cursors are recruited to the lymphoid organs, where antigen peptides, and injected into metastatic mela-
noma patients (Palucka et al., 2003). Effective antitumorthey differentiate into fully competent DCs, including
CD8 DCs, CD8 DCs, and B220 pDCs, supporting immunity and objective clinical responses were ob-
served in several patients. Interestingly, those patientsthe possibility that all DC subsets might derive from
a single DC common precursor (Martı´nez del Hoyo et that developed melanoma-specific CTLs survival signifi-
cantly longer than those that did not mount melanoma-al., 2002).
Marı´a L. Toribio (Madrid, Spain) focused on the devel- specific CTLs.
Eli Gilboa (Durham, USA) showed that in three phaseopmental origin of intrathymic DCs in humans and
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I/II clinical trials, the majority of patients treated with work-up of a previously performed trial showed that
mRNA transfected DCs exhibited T cell responses induced responses were polyclonal (Godelaine et al.,
against the mRNA-encoded antigens (Su et al., 2003). 2003). Disease stabilization and regression of individual,
To improve the immunopotency of the transfected DCs but not of all, metastases was observed in a significant
he described a method for enhancing the class II- proportion. Overall survival increased from 11–15 months
restricted presentation of endogenously expressed anti- in previous trials to 24 months in the closed class I 
gens by transiently inhibiting invariant chain expression II peptide trial (Schuler-Thurner et al., 2002) and will
using antisense oligonucleotides (Zhao et al., 2003). presumably be higher in the still ongoing second trial.
Mice immunized with antisense-treated mRNA trans-
fected DCs stimulated a more potent and longer lasting Concluding Remarks
CD4 and CD8 T cell response and exhibited enhanced Research on DCs continuously reveals novel regulatory
antitumor immunity. He also showed that immunizing capacities of this extremely plastic and versatile cell
against angiogenesis-associated products (such as type, which plays a crucial role in the initiation and con-
VEGFR-2, Tie-2, or VEGF) overexpressed in the tumor trol of immunity and tolerance, although paradoxically,
stroma inhibits tumor growth and argued that targeting DCs can also be responsible for the induction of some
stromal products could reduce the propensity of tumor pathogen-mediated and autoimmune diseases, allergic
cells escaping immune elimination (Nair et al., 2003). reactions, graft rejection, and failure of the immune sys-
Cornelis Melief (Leiden, The Netherlands) presented tem in the defense against tumor progression. There-
evidence that crosspresentation of tumor antigens to fore, a better understanding of DC immunobiology will
CD8 CTL occurs naturally for many tumors. This alone provide essential insights allowing the manipulation of
does not cause a tumoricidal CD8 CTL response. In the immune system through DCs and, consequently, the
many cases the suboptimal DC stimulation associated development of novel strategies for the treatment of
with tumor growth causes the CD8 T cells to remain microbial and parasitic infections, the control of graft
stuck as “poised” T cells in the tumor-draining LN. This rejection, and the improvement of DC-based immuno-
situation can be vastly exploited by DC stimulation therapeutic protocols for autoimmunity, allergy, and
through CD40 agonistic antibody or TLR ligands (CpG cancer.
ODN, LPS), leading to a systemic tumoricidal CD8 ef-
fector CTL expansion associated with tumor eradication Acknowledgments
(van Mierlo et al., 2002, and unpublished data).
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